Neoplastic transformation is often related to abnormal activation of growth factor receptors and their signaling pathways. The concept of targeting specific tumorigenic receptors and/or signaling molecules has been validated by the development and successful clinical application of drugs acting against the epidermal growth factor receptor 2 (HER2/neu, Erb2), the epidermal growth factor receptor 1 (EGFR, HER1), the Brc-Abl kinase, the platelet-derived growth factor receptor, and c-kit. This review will focus on the next promising therapeutic target, the insulin-like growth factor I receptor (IGF-IR). IGF-IR has been implicated in a number of neoplastic diseases, including several common carcinomas. From a pharmaceutical standpoint, of particular importance is that IGF-IR appears to be required for many transforming agents (genetic, viral, chemical) to act, but is not obligatory for the function of normal adult cells. The tumorigenic potential of IGF-IR is mediated through its antiapoptotic and transforming signaling, and in some cases through induction of prometastatic pathways. Preclinical studies demonstrated that downregulation of IGF-IR reversed the neoplastic phenotype and sensitized cells to antitumor treatments. The strategies to block IGF-IR function employed anti-IGF-IR antibodies, small-molecule inhibitors of the IGF-IR tyrosine kinase, antisense oligodeoxynucleotides and antisense RNA, small inhibitory RNA, triple helix, dominant-negative mutants, and various compounds reducing ligand availability. The experience with these strategies combined with the knowledge gained with current anti-growth factor receptor drugs should streamline the development of anti-IGF-IR therapeutics. Oncogene (2003 Oncogene ( ) 22, 6589-6597. doi:10.1038 Keywords: insulin-like growth factor receptor; anticancer drugs; antibodies; tyrosine kinase inhibitors; antisense; triple helix; dominant-negative mutants
Anti-growth factor receptor therapeutics
Several growth factor receptors with intrinsic tyrosine kinase activity have been implicated in the development and progression of neoplastic diseases. Growth factor receptor-driven tumorigenicity may be related to increased proliferation, suppression of apoptosis, especially under anchorage-independent conditions, and activation of processes favoring metastatic spread. Consequently, growth factor receptors became a rational target for therapeutic intervention (Shawver et al., 2002) . Such target-directed therapy is hoped to become an alternative to conventional nonselective treatments producing undesirable effects in normal cells. Various strategies have been pursued to inhibit tumorigenic effects of growth factors. Two approaches, that is, blocking target receptors by abolishing ligand/receptor binding and inactivating receptor tyrosine kinases with small-molecule inhibitors, provided the basis for the development of current antigrowth factor receptor drugs. The development, mechanisms of action, and clinical characteristics of these new pharmaceuticals have been extensively reviewed in recent publications (Mendelsohn and Baselga, 2000; Druker, 2002; Levitzki, 2002; Shawver et al., 2002; Arteaga, 2003; Fry, 2003) . Some of the target therapeutics are listed below as a reference for further discussion on the strategies to inactivate the insulin-like growth factor I receptor (IGF-IR).
The first antireceptor drug has been developed against the epidermal growth factor receptor 2 (HER2/neu, Erb2). HER2 is a type 1 transmembrane tyrosine kinase amplified in many cancers, including breast cancer, ovarian cancer, and stomach cancer (Mendelsohn and Baselga, 2000; Holbro et al., 2003) . HER2 overexpression typically is associated with more aggressive behavior and poor clinical outcome. In invasive breast cancer, high amplification of HER2 is seen in 25-30% of cases. More than a decade of research and clinical trials led to the launch of the anti-HER2 drug, Herceptin (Trastuzumab; Genentech), in 1998. Herceptin is a humanized monoclonal antibody (MAb) against HER2 and is indicated for the treatment of patients with metastatic breast cancer, whose tumors overexpress HER2. Herceptin is used both as first-line treatment in combination with paclitaxel, and as a second-and thirdline therapy (Harries and Smith, 2002; Shawver et al., 2002) . The extension of these applications to early breast cancer and other neoplastic diseases is being evaluated (www.clinicaltrials.gov).
The EGFR (HER1) and its ligands are often overexpressed in many types of human tumors (Mendelsohn and Baselga, 2000; Arteaga, 2003) . The therapeutic inhibition of EGFR has been achieved with two classes of compounds: humanized Abs binding and downregulating the receptor and small inhibitors inactivating the EGFR tyrosine kinase by blocking ATP binding site (Fry, 2003) . Presently, three humanized EGFR Abs are evaluated in clinical trials (Shawver et al., 2002; Arteaga, 2003) . Of these, the best developed is Cetuximab (erbitux, C225; Imclone), which is now under clinical assessment for the therapy of advanced colorectal cancer, squamous cell carcinoma, and pancreatic cancer (www.clinicaltrials.gov). Also, several small-molecule inhibitors of EGFR have entered the late stages of clinical development (Shawver et al., 2002; Fry, 2003) . One of them, Iressa (gefitinib, ZD1839; AstraZeneca), is a quinazoline competing with ATP for the binding site in the EGFR tyrosine kinase domain. Iressa has been already approved in Japan for the treatment of non-small-cell lung cancer (NSCLC) and its efficacy as a single agent or in combination with other therapies to treat NSCLC and other cancers is under evaluation in the US clinical trials (www.clinicaltrials.gov).
Another successful antityrosine kinase drug is Gleevec (imatinib mesylate, STI571; Novartis). Gleevec is a small-molecule inhibitor blocking the Bcr-Abl cytoplasmic tyrosine kinase that is constitutively active in patients with chronic myelogenous leukemia (CML), and in 15-30% adults with acute lymphoblastic leukemia. Gleevec is also active against the tyrosine kinases of the platelet-derived growth receptor and c-kit, which are often hyperactivated in brain tumors and gastrointestinal stromal tumors (GIST), respectively (Shawver et al., 2002) . Currently, Gleevec is indicated for the treatment of CML and advanced GIST carrying an activating c-kit mutation, and its possible use against other malignancies is under investigation (Hernandez-Boluda and Cervantes, 2002; Druker, 2002; www.clinicaltrials.gov) . Other recently developed antigrowth factor receptor compounds include inhibitors of the tyrosine kinase of the vascular endothelial growth factor receptor 2 (VEGFR2). These compounds appear to reduce tumor neovascularization, halting its enlargement and expansion (Shawver et al., 2002) .
The clinical success with Herceptin, Iressa, and Gleevec validates the concept of anti-growth factor therapy and justifies the pursuit of strategies against similar targets. This review will focus on the next promising pharmaceutical target, IGF-IR.
IGF-IR and its signaling
IGF-IR is an evolutionary conserved, ubiquitous transmembrane tyrosine kinase structurally similar to the insulin receptor (IR) (Ullrich et al., 1986) . IGF-IR is composed of two extracellular alpha subunits and two intracellular beta subunits (Figure 1 ). The alpha subunits bind ligands (IGF-I, IGF-II, and insulin at supraphysiological doses), while beta subunits transmit ligand-induced signal. The beta subunits contain three major domains: the juxtamembrane domain, tyrosine kinase domain, and the C-terminus (Figure 1 ). The tyrosine kinase domain shares high (B85%) homology with its counterpart in IR, while the C-terminus is only B40% homologous with the C-terminus of IR (Ullrich et al., 1986) .
Binding of ligands to IGF-IR induces its autophosphorylation and tyrosine phosphorylation of IGF-IR substrates, especially the IR substrate 1 (IRS-1) and srcand collagen-homology (SHC) protein. Tyrosine-phosphorylated IRS-1 and SHC bind different effector proteins (enzymes and/or adapters) inducing multiple signaling cascades, among them several interconnecting pathways controlling cell survival and proliferation (Shepherd et al., 1998; White, 1998 White, , 2002 Adams et al., 2000; O'Connor et al., 2000; Surmacz, 2000) . The critical survival pathway activated by IGF-I stems from IRS-1. IRS-1 recruits and stimulates the PI-3 kinase (PI-3K), which then transmits signal to the serine/ threonine kinase Akt (Akt). Activated Akt phosphorylates and blocks a variety of proapoptotic proteins, including BAD, caspase-9, forkhead transcription factors, and the GSK-3 beta kinase. Furthermore, Akt induces the expression of antiapoptotic proteins, for example, Bcl-2 (Brazil et al., 2002; Hill and Hemmings, 2002; Nicholson and Anderson, 2002) . Other mitogenic/ survival IGF-IR pathways involve signal transducers and activators of transcription (STATs) that are phosphorylated and activated by IGF-I through JAK1/2 and PI-3K/Akt pathways (Zong et al., 1998 (Zong et al., , 2000 . In addition, IGF-IR can prevent cell death or induce proliferation via the SHC/Ras/ERK1/2 pathway .
While antiapoptotic and growth pathways of IGF-IR have been extensively studied, the signals controlling nonmitogenic functions of IGF-IR, such as cellsubstrate adhesion, migration, invasion, or intracellular interactions are less well understood. There is increasing evidence that IGF-IR pathways interconnect with integrin and cadherin signaling systems (Vuori and Ruoslahti, 1994; Guvakova and Surmacz, 1999; Mauro et al., 1999 Mauro et al., , 2003 Reiss et al., 2001a; Shaw, 2001) . In some experimental models, IGF-IR has been shown to mediate metastasis, possibly through enhanced migration (Doerr and Jones, 1996; Bartucci et al., 2001) , reduced cell-cell adhesion (Mauro et al., 2003) , and upregulation of plasminogen activator uPA and matrix metalloproteinases (Long et al., 1998; Mira et al., 1999; Dunn et al., 2001; Zhang and Brodt, 2003) .
IGF-IR structure-function studies
The extensive mutational analysis of IGF-IR identified receptor domains required for the initiation of specific pathways and linked these pathways with specific functions, that is, proliferation (measured as cell growth in monolayer), survival (usually measured as the ability of cells to survive under anchorage-independent conditions), and transformation (assessed as the ability to grow in soft agar or to form foci). The experiments using different cell models unequivocally demonstrated that the mutation in the ATP binding site of the IGF-IR tyrosine kinase domain produced 'dead' receptors incapable of signal transmission ( Figure 1 ). Mutations at other residues of the tyrosine kinase impaired IGF-IR only partially. For instance, the substitutions of tyrosines (Tyr) 1131, 1135, and 1136 into phenylalanines abrogated transforming signaling and mitogenesis, but not survival signaling. Mutations in either Tyr 1131 or Tyr 1135 downregulated transformation without reducing cell growth. Tyr 950 in the IGF-IR juxtamembrane domain was found necessary for IRS and SHC binding, and for induction of mitogenic and transforming activity, but the IGF-IR/Tyr 950 mutant still transmitted antiapoptotic signaling, confirming that in addition to the classic IRS-1-dependent PI-3K/Akt pathway, other survival pathway(s) emanate from IGF-IR (Hongo et al., 1996; O'Connor et al., 1997; O'Connor, 1998; Romano et al., 1999) .
Deletion of the entire C-terminus at aa 1229 totally abrogated transforming function, without inhibiting mitogenic and antiapoptotic ability (Surmacz et al., 1995) . The 'transforming domain' was mapped between residues 1245 and 1310, with Tyr 1251, Ser 1280-1283, His 1293, and Lys 1294 required for transformation (Hongo et al., 1996) (Figure 1 ). It is worth nothing that C-terminal deletions (at residue 1229 or 1245) appeared to amplify antiapoptotic effects, suggesting that the C-terminus acts as an intrinsic inhibitor of IGF-IR survival signaling. The mutations in the C-terminus at Tyr 1250/1251, His 1293, and Lys 1294 reduced survival, implying that these residues act as neutralizers of the C-terminus proapoptotic function (Hongo et al., 1996; O'Connor, 1998) .
The important practical implication of the above studies is that transformation by IGF-IR does not occur without activated IGF-I survival pathways. Thus, targeting the survival function of IGF-IR should be the optimal approach to inhibit tumorigenicity. As evidenced by the mutational analysis, the best way to achieve this affect is to inactivate totally the IGF-IR tyrosine kinase.
IGF-IR and tumorigenesis
Initially, the importance of IGF-IR in tumorigenesis was suggested by the observation that constitutive overexpression of IGF-IR and/or hyperactivation of its signaling induced the transformed phenotype in cultured cells (Kaleko et al., 1990; Pietrzkowski et al., 1992a) . Later experiments with cells derived from IGF-IR knockout mice provided evidence that different tumorigenic agents (viral, chemical, genetic) were not able to induce transformation in the absence of IGF-IR, but were transforming when IGF-IR (but not IR) was re-expressed (Baserga, 1994 (Baserga, , 1995 (Baserga, , 1998 . This controlling function of IGF-IR most likely depends on its ability to counteract strong susceptibility to apoptosis observed in transformed cells (Baserga, 1996 (Baserga, , 1997 (Baserga, , 1998 . Additional important observation stemming from the studies on IGF-IR knockout cells and normal human fibroblasts was that normal, untransformed cells are more resistant to apoptosis and can survive, or even proliferate (albeit at slower rate), in the absence of functional IGF-IR (Baserga, 1998) . Thus, transformed but not normal cells should be especially sensitive to anti-IGFIR drugs.
In vitro experiments with tumor cell lines and epidemiological studies provided evidence that activation of IGF-IR is implicated in the development of many common neoplastic diseases, including carcinomas of lung, breast, prostate, pancreas, liver, and colon (Korc, 1998; Pollak, 2000; Surmacz, 2000; Djavan et al., 2001; Giovannucci, 2001; Sachdev and Yee, 2001; Scharf et al., 2001; Druckmann and Rohr, 2002) . In some diseases, for instance in primary breast cancer, IGF-IR is overexpressed and hyperphosphorylated compared with its status in normal mammary epithelial cells (Surmacz, 2000) . Hyperactivation of IGF-IR may result from autocrine or paracrine stimulation, as many tumors produce IGF-IR ligands (Sachdev and Yee, 2001 ). In addition, high abundance of endocrine IGFs may enhance IGF-IR signal. In this context, it is worth noting that elevated plasma concentrations of IGF-I have been linked with increased risk of several types of cancer (Pollak, 2000) . Similarly, data from experimental systems demonstrated that elevated IGF-I levels correlate with increased tumorigenicity in experimental models (Dunn et al., 1997; Butler et al., 1998) .
Targeting IGF-IR and its signaling IGF-IR fulfills several criteria of an attractive pharmaceutical target: (1) IGF-IR is implicated in neoplastic transformation; (2) abundance of IGF-IR and its ligands can be easily measured in clinical samples; and (3) in vitro studies identified critical parameters for IGF-IR induction. The greatest challenge in targeting IGF-IR is designing strategies that would specifically inhibit IGF-IR without blocking IR and producing diabetogenic effects. The stage for anti-IGF-IR drugs has been set by a variety of laboratory studies, demonstrating that inhibition of either IGF-IR/ligand binding, IGF-IR expression, or IGF-I signaling can exert antitumor effects. Several of these approaches are discussed below.
Antibodies
The initial approach to inhibit IGF-IR signaling was based on the use of IGF-IR blocking antibodies (Figure 2b) . The mouse MAb alpha-IR-3 raised against the alpha domain of IGF-IR inhibited IGF-IR activation and IGF-IR-dependent mitogenicity in several cell types in vitro, including breast carcinoma (Arteaga et al., 1989; Arteaga, 1992) , rhabdomyosarcoma (Kalebic et al., 1994) , NSCLC (Zia et al., 1996) , and Ewing's sarcoma (Scotlandi et al., 1998) . However, in some cases alpha-IR-3 was ineffective in blocking IGF-I-sensitive tumors in animal models (Arteaga, 1992) . Furthermore, it has been reported that alpha-IR-3 may exhibit agonistic abilities towards IGF-IR (De Leon et al., 1992; Kato et al., 1993) .
The mouse anti-IGF-IR MAb 391 inhibited IGF-IR autophosphorylation and signaling to Akt in several human cancer cell lines. Chronic treatment with MAb 391 resulted in downregulation of receptors through lysosome-dependent pathways (Hailey et al., 2002) . Several other mouse anti-IGF-IR MAbs were described (Li et al., 1993 (Li et al., , 2000 . One of them, MAb 1H7, which blocks IGF-IR/IGF-I binding and IGF-IR-dependent DNA synthesis was used to engineer a single-chain humanized anti-IGF-IR scFv-Fc Ab and contains the Fc domain of human IgG1 fused to the Fv region of 1H7 (Li et al., 2000) . Treatment of MCF-7 breast cancer cells with scFv-Fc for 2-24 h downregulated the levels of IGF-IR through the lysosomal/endocytic pathway, rendering the cells refractory to IGF-I stimulation (Sachdev et al., 2003) . Importantly, downregulation of IGF-IR by scFv-Fc occurred also in MCF-7 xenografts Growth factor receptors as therapeutic targets E Surmacz and was paralleled by reduced tumor growth (Sachdev et al., 2003) . These or similar humanized MAbs will likely become a model for future drug development once their specificity towards IGF-IR and lack of IR crossreactivity is demonstrated in vivo.
Low molecular weight molecules targeting IGF-IR tyrosine kinase
High-throughput technology combined with computer modeling is currently used to identify low molecular weight compounds blocking the IGF-IR tyrosine kinase (Figure 2c ). The first described IGF-IR inhibitors, tyrphostins AG 538 and I-OMeAG, were modeled on the IR tyrosine kinase. The compounds inactivated the IGF-IR tyrosine kinase by blocking the substrate binding site; however, crossreactivity with the IR tyrosine kinase was reported (Blum et al., 2000) . Recent advances in the characterization of the threedimensional structures of IGF-IR and IR greatly facilitated the design of specific IGF-IR inhibitors (De Meyts and Whittaker, 2002) . Most importantly, crystallographic studies revealed conformational differences in the phosphorylated forms of IGF-IR and IR kinases, the feature allowing the development of selective therapeutics (Favelyukis et al., 2001; Pautsch et al., 2001) . Several new compounds with enhanced specificity towards IGF-IR and low crossreactivity with IR entered into preclinical studies. The examples include derivatives of pyrimidine and podophyllotoxin, disclosed in patent applications WO 02/092599 and WO 02/102804, respectively. Specific small inhibitors of IGF-IR are likely candidates to become anti-IGF-IR drugs. The positive experience with similar therapeutics (Iressa, Gleevec), especially the possibility of oral delivery and low toxicity, makes this approach especially attractive.
IGF-I mimetic peptides
A series of small IGF-I peptide analogues was designed by molecular modeling of the IGF-I protein (Pietrzkowski et al., 1992b (Pietrzkowski et al., , 1993 to compete with IGF-IR ligands (Figure 2d ). The synthetic peptides were modeled on C and D domains of IGF-I, as these domains contain the least similarity between IGF-I and insulin. One of the peptides, JB1 (modeled on the D domain) effectively inhibited IGF-I-dependent IGF-IR autophosphorylation and proliferation in several tumor cell lines. The analogues used at nano-or micromolar concentrations exhibited good specificity for IGF-IR, and low toxicity for cells in cell culture (Pietrzkowski et al., 1992b (Pietrzkowski et al., , 1993 . However, the efficacy of these compounds against experimental tumors in vivo has never been assessed.
Modulators of IGF-IR internalization and recycling
Following ligand binding, the IGF-IR/ligand complex is internalized, the ligand is degraded by endosomal proteinases, and the receptor is returned to the membrane. One way to reduce IGF-I effects is to block IGF-IR re-expression on the cell surface. Recent studies suggested that IGF-IR trafficking could be substantially blocked by the inhibition of IGF-I-degrading enzymes, for example, cathepsin. The cathepsin inhibitors, E-64-and CA074-methyl ester, reduced IGF-IR expression on the cell surface and impaired several IGF-I-dependent effects, including DNA synthesis, cell survival, anchorage-independent growth, and synthesis of matrix metalloproteinases in human breast cancer and murine lung carcinoma cells (Brodt et al., 2000; Navab et al., 2001) .
Antisense nucleotides, antisense RNA, siRNA, triple helix A variety of experiments employing antisense oligodeoxynucleotides (ODNs), antisense RNA, and small interfering RNA (siRNA) demonstrated that IGF-IRdependent tumorigenicity can be decreased or eliminated by blocking IGF-IR mRNA, thus inhibiting IGF-IR protein synthesis (Figure 2a) . Most of the reported anti-IGF-IR ODNs contained sequences complementary to the IGF-IR translation initiation site. The association of these reagents with IGF-IR mRNA produced heteroduplex that was cleaved by RNase H. Multiple studies documented that anti-IGF-IR ODNs (regular or phosphorotioate chemistry) at nanomolar concentrations decreased IGF-IR expression, reduced cell proliferation, and induced apoptosis in various human and rodent cancer cell types in cells grown in culture (Pietrzkowski et al., 1993; Resnicoff et al., 1994 Resnicoff et al., , 1995a Muller et al., 1998; Coppola et al., 1999; Macaulay et al., 2001; Pavelic et al., 2002; Bohula et al., 2003) . Furthermore, in some instances, treatment with ODNs induced massive apoptosis and tumor regression in animal models (Resnicoff et al., 1995a, b) . However, the reduction of IGF-IR expression was often incomplete even with high concentrations (100-500 nm) of ODNs, possibly due to their poor association with target sequences (Macaulay et al., 2001) . Moreover, interactions of anti-IGF-IR ODNs with IR synthesis were reported (Bohula et al., 2003) .
To address these problems, Bohula et al. (2003) used scanning oligonucleotide arrays to probe the secondary structure of IGF-IR mRNA in order to identify target sequences that are accessible for ODNs, and do not appear in IR mRNA. This strategy enabled selection of specific ODNs that effectively and selectively downregulated IGF-IR in human cancer cell lines (Bohula et al., 2003) . Furthermore, the accessible sequences were suitable targets for anti-IGF-IR siRNAs. Indeed, some of the designed siRNAs were able to silence target IGF-IR mRNA sequences. The effect was paralleled by repression of IGF-IR synthesis and downregulation of IGF-IR signaling (Bohula et al., 2003) .
In addition to ODNs and siRNA, different antisense-IGF-IR RNA vectors containing fragments of IGF-IR cDNA cloned in 3 0 -5 0 orientation were generated to (Nakamura et al., 2000) , Ewing's sarcoma (Scotlandi et al., 2002) , and rat glioblastoma (Resnicoff et al., 1994) . The expression of this IGF-IR antisense efficiently inhibited tumorigenicity of cells grown as explants in experimental animals, most probably by induction of massive apoptosis (Resnicoff et al., 1994 (Resnicoff et al., , 1995b Scotlandi et al., 2002) . The same antisense construct inhibited metastasis of murine lung carcinoma cells (Brodt et al., 2000) . Another antisense IGF-IR plasmid containing B300 bp DNA complementary to the region surrounding the IGF-IR translation initiation site was used to inhibit IGF-IR expression and function in breast cancer cells (Neuenschwander et al., 1995) .
In human rhabdomyosarcoma cells, transfection of an antisense IGF-IR plasmid containing sequences complementary to the first 700 bp of IGF-IR coding sequence markedly reduced growth rates in monolayer and soft agar and impaired tumor formation in immunodeficient mice (Shapiro et al., 1994) . This antisense delivered to human lung cancer cells decreased the expression of IGF-IR, inhibited growth in soft agar, and prolonged the survival of animals bearing established xenografts (Lee et al., 1996) . A similar plasmid containing a 697 bp fragment exon 1-3 was effective in decreasing the growth and metastasis of breast cancer cells (Chernicky et al., 2000) and rat prostate cancer cells (Burfeind et al., 1996) .
In many cases, the induction of cell death with antisense IGF-IR strategies was much more pronounced in vivo (animal models) than in vitro (monolayer tissue culture or soft agar), suggesting that in vivo tests may be superior in screening for anti-IGF-IR compounds (Resnicoff et al., 1995a, b; Nakamura et al., 2000) .
Oligonucleotide-directed triple helix formation is an approach to block transcription of specific genes by inhibiting the passage of RNA polymerase along target DNA. The third effector strand (oligoribonucleotide) contains oligopurine sequences potentially capable of forming a triple helix with oligopurine and/or oligopyrimidine sequenced in target DNA. The triple helix strategy has been reported to be effective in downregulation of IGF-IR. Specifically, a plasmid encoding the homopurine RNA sequences designed to form a triplex with a homopurine Á homopyrimidine sequence present 3 0 to the termination codon of the IGF-IR gene suppressed IGF-IR transcription in rat C6 glioblastoma cells. The triple helix reagent induced dramatic reduction of IGF-IR transcripts and IGF-IR expression and inhibited tumor formation in nude mice (Rininsland et al., 1997) .
Interestingly, in the case of rat C6 glioblastoma and some other cellular models, downregulation of IGF-IR by antisense approaches was associated with the induction of an immune host response leading to elimination of untreated established tumors (Resnicoff et al., 1994; Baserga, 1998; ) . This peculiar effect, perhaps related to the induction of immune response by the presence of apoptotic cells (Trojan et al., 2002) , was further explored in pilot studies involving patients with astrocytomas treated with autologous glioma cells exposed to anti-IGF-IR ODNs (Andrews et al., 2001) .
Dominant-negative mutants and mini-receptors
A variety of mutant IGF-IRs with deletions of different sizes and substitutions of critical residues were delivered (by transfection or infection) to IGF-I-sensitive cells to test their dominant-negative potential against wild-type receptors (Figure 2e ). Different mutations in the tyrosine kinase domain (ATP binding site, Tyr 1131, 1135, 1136) were reported to reduce IGF-IR-dependent proliferation in monolayer. In addition, mutations in the C-terminus, especially Tyr 1250/1251 inhibited anchorage-independent growth or foci formation, but had only limited effects on cell proliferation (Burgaud et al., 1995; Blakesley et al., 1996; Kalebic et al., 1998; Brodt et al., 2001; Seely et al., 2002) . In some experimental models, the mutations in the tyrosine kinase domain and in Tyr 1250/1251 reduced tumor development in animals (Blakesley et al., 1996; Seely et al., 2002) , while in other studies these mutations did not exhibit a dominantnegative effect in vivo (Burgaud et al., 1995) .
More consistent antitumorigenic effects in vivo were obtained with IGF-IR mutants containing large truncations. Two mutants encoding only alpha subunits (468/ STOP and 482/STOP) reduced tumor growth in animals and produced extensive apoptosis in vivo. In addition, the mutants exhibited a bystander effect against the neighboring wild-type cells Reiss et al., 1998; Adachi et al., 2002; Lee et al., 2003) . Furthermore, 468/STOP inhibited experimental metastasis (Dunn et al., 1998) . The mechanism of action of these STOP mutants is not fully understood. On the one hand, they are secreted proteins that are able to bind ligands reducing their bioavailability Lee et al., 2003) . On the other hand, 468/STOP has been found in the cytoplasm of the producing cells and reported to inhibit endogenous IGF-IR synthesis (Reiss et al., 2001b) . Other two truncated receptors 950/ STOP and 952/STOP that lack most of the beta subunit (including the IGF-IR tyrosine kinase) inhibited tumor growth in animals and IGF-IR signaling in vitro (Prager et al., 1994; Lee et al., 2003) . These receptors most likely block IGF-IR activity by dimerization with endogenous wild-type receptors.
An innovative approach to reduce IGF-IR-dependent survival involved mini-receptors expressing C-terminal domains (Figure 2f ). Since deletion of the entire C-terminus enhanced survival, overexpression of this domain was expected to increase apoptosis. Indeed, mini-receptors containing the last 108 aa of IGF-IR (CF) spliced to the myristylation signal (MyCF) to ensure cell membrane association induced apoptosis in many cell types, sensitized cells to UV irradiation, and abrogated tumorigenesis in nude mice. Furthermore, mutations of MyCF at residues that were previously found to silence proapoptotic activity of the C-terminus reduced its antitumor potential (Hongo et al., 1998; Liu et al., 1998) .
Downregulation of IGF-IR ligands
Since high levels of IGF-IR ligands have been implicated in the etiology of many neoplastic diseases, strategies to reduce ligand availability have been developed as possible therapeutics (Figure 2g) . The strategies to downregulate ligand expression or availability included the use of ribosymes, RNA enzymes that specifically cleave target RNAs (Guo et al., 2003) , triple helix, and antisense RNA (Trojan et al., 2002) , and overexpression of IGF-I binding proteins (Yee, 2002) .
Combined strategies
The downregulation of IGF-IR has been shown to increase sensitivity to different conventional antitumor treatments (Baserga, 1998) . Thus, the use of anti-IGF-IR compounds in combination with other therapies can be envisioned. In addition, cells refractory to other treatments (e.g. anti-HER2 drugs) may present IGF-I sensitivity, thus addition of anti-IGF-IR therapy may improve current antigrowth factor receptor approaches (Lu et al., 2001) .
Perspectives for anti-IGF-IR pharmaceuticals
IGF-IR is a promising target in cancer therapy because: (1) IGF-IR expression is easily measurable by conventional techniques; (2) tumor cells may be more sensitive to targeting IGF-IR than normal cells; and (3) IGF-IR is often required for the tumorigenic effects of other oncogenic agents. Thus targeting IGF-IR can be combined with other therapies. Unlike with HER2 and EGFR, the development of anti-IGF-IR pharmaceuticals is still in early discovery phases. Similar to HER2 and EGFR, however, the most advanced strategies are those involving small inhibitors of the IGF-IR tyrosine kinase and anti-IGF-IR antibodies. Other approaches, such as siRNA, antisense, and triple helix strategies are also promising, but they will require optimization of specificity in vivo and efficient and safe delivery systems.
